A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Authors
Keywords
HER2-overexpressing breast cancer, Cancer immunotherapeutic, dHER2 protein, Vaccine
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 156, Issue 2, Pages 319-330
Publisher
Springer Nature
Online
2016-03-19
DOI
10.1007/s10549-016-3751-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
- (2014) Yun Shi et al. BREAST CANCER RESEARCH
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
- (2014) C. T. Campbell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pertuzumab Protects the Achilles' Heel of Trastuzumab--Emtansine
- (2013) W. R. Gwin et al. CLINICAL CANCER RESEARCH
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
- (2013) Tao Qin et al. OncoTargets and Therapy
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- MVA–5T4-induced immune responses are an early marker of efficacy in renal cancer patients
- (2011) Richard Harrop et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeted therapies for breast cancer
- (2011) Michaela J. Higgins et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients
- (2010) Richard Harrop et al. JOURNAL OF IMMUNOTHERAPY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non-Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine
- (2008) B. Garcia et al. CLINICAL CANCER RESEARCH
- Cancer vaccines: on the threshold of success
- (2008) Leisha A Emens EXPERT OPINION ON EMERGING DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now